Reduced-dose cabazitaxel is non-inferior to the standard dose for patients with metastatic castration-resistant prostate cancer (mCRPC) who previously received docetaxel, according to... Read More
The addition of abiraterone acetate and prednisone (AAP) or docetaxel and prednisone (DocP) to standard of care (SOC) may improve... Read More
Patients who take statins after prostate cancer (PC) diagnosis may have a reduced risk of mortality, according to a study published in... Read More
Newly diagnosed patients with metastatic, castration-sensitive prostate cancer may have significantly prolonged overall survival (OS) and radiographic progression-free survival (PFS)... Read More
Genomic testing and immunomodulation may help to improve outcomes among patients with prostate cancer, according to a study published in... Read More
Active surveillance and watchful waiting are emerging as important management options for men diagnosed with early-stage prostate cancer. Patients do not,... Read More
Evidence from a long term follow-up published in the New England Journal of Medicine suggests that prostatectomy may not improve... Read More
Improvements in the technology used to capture circulating tumor cells (CTCs) may offer a better way to understand prostate cancer... Read More
Early switching from docetaxel to cabazitaxel or vice versa may lead to improved prostate-specific antigen (PSA) response rates, according to... Read More
An automated bone scan index (aBSI) at baseline is clinically validated as a prognostic biomarker in men with castration-resistant prostate... Read More
